Diabetes-induced coronary vascular dysfunction involves increased arginase activity

Maritza J. Romero, Daniel H. Platt, Huda E. Tawfik, Mohamed Labazi, Azza B. El-Remessy, Manuela Bartoli, Ruth B. Caldwell, Robert W. Caldwell

Research output: Contribution to journalArticle

241 Citations (Scopus)

Abstract

Increases in arginase activity have been reported in a variety of disease conditions characterized by vascular dysfunction. Arginase competes with NO synthase for their common substrate arginine, suggesting a cause and effect relationship. We tested this concept by experiments with streptozotocin diabetic rats and high glucose (HG)-treated bovine coronary endothelial cells (BCECs). Our studies showed that diabetes-induced impairment of vasorelaxation to acetylcholine was correlated with increases in reactive oxygen species and arginase activity and arginase I expression in aorta and liver. Treatment of diabetic rats with simvastatin (5 mg/kg per day, subcutaneously) or l-citrulline (50 mg/kg per day, orally) blunted these effects. Acute treatment of diabetic coronary arteries with arginase inhibitors also reversed the impaired vasodilation to acetylcholine. Treatment of BCECs with HG (25 mmol/L, 24 hours) also increased arginase activity. This effect was blocked by treatment with simvastatin (0.1 μmol/L), the Rho kinase inhibitor Y-27632 (10 μmol/L), or l-citrulline (1 mmol/L). Superoxide and active RhoA levels also were elevated in HG-treated BCECs. Furthermore, HG significantly diminished NO production in BCECs. Transfection of BCECs with arginase I small interfering RNA prevented the rise in arginase activity in HG-treated cells and normalized NO production, suggesting a role for arginase I in reduced NO production with HG. These results indicate that increased arginase activity in diabetes contributes to vascular endothelial dysfunction by decreasing l-arginine availability to NO synthase.

Original languageEnglish (US)
Pages (from-to)95-102
Number of pages8
JournalCirculation research
Volume102
Issue number1
DOIs
StatePublished - Jan 1 2008

Fingerprint

Arginase
Blood Vessels
Endothelial Cells
Glucose
Citrulline
Simvastatin
Vasodilation
Nitric Oxide Synthase
Acetylcholine
Arginine
rho-Associated Kinases
Streptozocin
Superoxides
Small Interfering RNA
Transfection
Aorta
Reactive Oxygen Species
Coronary Vessels

Keywords

  • Arginine
  • Coronary arteries
  • Diabetes
  • Endothelial nitric oxide synthase
  • Oxidative stress
  • Vascular endothelial function
  • Vasodilation

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Diabetes-induced coronary vascular dysfunction involves increased arginase activity. / Romero, Maritza J.; Platt, Daniel H.; Tawfik, Huda E.; Labazi, Mohamed; El-Remessy, Azza B.; Bartoli, Manuela; Caldwell, Ruth B.; Caldwell, Robert W.

In: Circulation research, Vol. 102, No. 1, 01.01.2008, p. 95-102.

Research output: Contribution to journalArticle

Romero, Maritza J. ; Platt, Daniel H. ; Tawfik, Huda E. ; Labazi, Mohamed ; El-Remessy, Azza B. ; Bartoli, Manuela ; Caldwell, Ruth B. ; Caldwell, Robert W. / Diabetes-induced coronary vascular dysfunction involves increased arginase activity. In: Circulation research. 2008 ; Vol. 102, No. 1. pp. 95-102.
@article{9639e3862cd34eb294709ee0496be40b,
title = "Diabetes-induced coronary vascular dysfunction involves increased arginase activity",
abstract = "Increases in arginase activity have been reported in a variety of disease conditions characterized by vascular dysfunction. Arginase competes with NO synthase for their common substrate arginine, suggesting a cause and effect relationship. We tested this concept by experiments with streptozotocin diabetic rats and high glucose (HG)-treated bovine coronary endothelial cells (BCECs). Our studies showed that diabetes-induced impairment of vasorelaxation to acetylcholine was correlated with increases in reactive oxygen species and arginase activity and arginase I expression in aorta and liver. Treatment of diabetic rats with simvastatin (5 mg/kg per day, subcutaneously) or l-citrulline (50 mg/kg per day, orally) blunted these effects. Acute treatment of diabetic coronary arteries with arginase inhibitors also reversed the impaired vasodilation to acetylcholine. Treatment of BCECs with HG (25 mmol/L, 24 hours) also increased arginase activity. This effect was blocked by treatment with simvastatin (0.1 μmol/L), the Rho kinase inhibitor Y-27632 (10 μmol/L), or l-citrulline (1 mmol/L). Superoxide and active RhoA levels also were elevated in HG-treated BCECs. Furthermore, HG significantly diminished NO production in BCECs. Transfection of BCECs with arginase I small interfering RNA prevented the rise in arginase activity in HG-treated cells and normalized NO production, suggesting a role for arginase I in reduced NO production with HG. These results indicate that increased arginase activity in diabetes contributes to vascular endothelial dysfunction by decreasing l-arginine availability to NO synthase.",
keywords = "Arginine, Coronary arteries, Diabetes, Endothelial nitric oxide synthase, Oxidative stress, Vascular endothelial function, Vasodilation",
author = "Romero, {Maritza J.} and Platt, {Daniel H.} and Tawfik, {Huda E.} and Mohamed Labazi and El-Remessy, {Azza B.} and Manuela Bartoli and Caldwell, {Ruth B.} and Caldwell, {Robert W.}",
year = "2008",
month = "1",
day = "1",
doi = "10.1161/CIRCRESAHA.107.155028",
language = "English (US)",
volume = "102",
pages = "95--102",
journal = "Circulation Research",
issn = "0009-7330",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Diabetes-induced coronary vascular dysfunction involves increased arginase activity

AU - Romero, Maritza J.

AU - Platt, Daniel H.

AU - Tawfik, Huda E.

AU - Labazi, Mohamed

AU - El-Remessy, Azza B.

AU - Bartoli, Manuela

AU - Caldwell, Ruth B.

AU - Caldwell, Robert W.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Increases in arginase activity have been reported in a variety of disease conditions characterized by vascular dysfunction. Arginase competes with NO synthase for their common substrate arginine, suggesting a cause and effect relationship. We tested this concept by experiments with streptozotocin diabetic rats and high glucose (HG)-treated bovine coronary endothelial cells (BCECs). Our studies showed that diabetes-induced impairment of vasorelaxation to acetylcholine was correlated with increases in reactive oxygen species and arginase activity and arginase I expression in aorta and liver. Treatment of diabetic rats with simvastatin (5 mg/kg per day, subcutaneously) or l-citrulline (50 mg/kg per day, orally) blunted these effects. Acute treatment of diabetic coronary arteries with arginase inhibitors also reversed the impaired vasodilation to acetylcholine. Treatment of BCECs with HG (25 mmol/L, 24 hours) also increased arginase activity. This effect was blocked by treatment with simvastatin (0.1 μmol/L), the Rho kinase inhibitor Y-27632 (10 μmol/L), or l-citrulline (1 mmol/L). Superoxide and active RhoA levels also were elevated in HG-treated BCECs. Furthermore, HG significantly diminished NO production in BCECs. Transfection of BCECs with arginase I small interfering RNA prevented the rise in arginase activity in HG-treated cells and normalized NO production, suggesting a role for arginase I in reduced NO production with HG. These results indicate that increased arginase activity in diabetes contributes to vascular endothelial dysfunction by decreasing l-arginine availability to NO synthase.

AB - Increases in arginase activity have been reported in a variety of disease conditions characterized by vascular dysfunction. Arginase competes with NO synthase for their common substrate arginine, suggesting a cause and effect relationship. We tested this concept by experiments with streptozotocin diabetic rats and high glucose (HG)-treated bovine coronary endothelial cells (BCECs). Our studies showed that diabetes-induced impairment of vasorelaxation to acetylcholine was correlated with increases in reactive oxygen species and arginase activity and arginase I expression in aorta and liver. Treatment of diabetic rats with simvastatin (5 mg/kg per day, subcutaneously) or l-citrulline (50 mg/kg per day, orally) blunted these effects. Acute treatment of diabetic coronary arteries with arginase inhibitors also reversed the impaired vasodilation to acetylcholine. Treatment of BCECs with HG (25 mmol/L, 24 hours) also increased arginase activity. This effect was blocked by treatment with simvastatin (0.1 μmol/L), the Rho kinase inhibitor Y-27632 (10 μmol/L), or l-citrulline (1 mmol/L). Superoxide and active RhoA levels also were elevated in HG-treated BCECs. Furthermore, HG significantly diminished NO production in BCECs. Transfection of BCECs with arginase I small interfering RNA prevented the rise in arginase activity in HG-treated cells and normalized NO production, suggesting a role for arginase I in reduced NO production with HG. These results indicate that increased arginase activity in diabetes contributes to vascular endothelial dysfunction by decreasing l-arginine availability to NO synthase.

KW - Arginine

KW - Coronary arteries

KW - Diabetes

KW - Endothelial nitric oxide synthase

KW - Oxidative stress

KW - Vascular endothelial function

KW - Vasodilation

UR - http://www.scopus.com/inward/record.url?scp=37849019273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37849019273&partnerID=8YFLogxK

U2 - 10.1161/CIRCRESAHA.107.155028

DO - 10.1161/CIRCRESAHA.107.155028

M3 - Article

C2 - 17967788

AN - SCOPUS:37849019273

VL - 102

SP - 95

EP - 102

JO - Circulation Research

JF - Circulation Research

SN - 0009-7330

IS - 1

ER -